A Study of Picoplatin in Colorectal Cancer

A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer

Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer. One of the most active treatment combinations is known as FOLFOX, which is a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. Oxaliplatin is a type of platinum drug and was approved by the FDA in 2004. While generally well-tolerated, oxaliplatin may cause toxicity to the nerves, such as sensory loss or cold sensitivity.

Picoplatin is a new type of platinum drug that has shown activity with 5-FU in pre-clinical studies and has undergone extensive Phase 1 and Phase 2 testing in a variety of cancers. No significant nerve toxicity has been seen in previous studies of picoplatin.

This study will review the safety and effectiveness of FOLPI, which is the combination of 5-FU and leucovorin with picoplatin in participants with colorectal cancer.

Study Overview

• Status: Unknown
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin; Drug: FOLPI; Drug: FOLFOX

Detailed Description

Subjects will be randomized centrally to treatment with picoplatin administered either every two or every four weeks and will be assigned a dose of picoplatin dependent on the study results to date. Each patient will also receive therapy every two weeks with 5-FU and leucovorin. In each schedule, the cohort size will be 3 subjects, to be expanded to 6 subjects if a dose-limiting toxicity is observed. If not dose-limiting toxicity observed among the 3 subjects within a cohort, picoplatin dose escalation may proceed, until the maximum tolerated dose is established.

• Study Type: Interventional
• Enrollment (Anticipated): 43
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Russian Federation
  • Astrakhan, Russian Federation, 414041
    • Regional Oncology Center - Phase 2
  • Chelyabinsk, Russian Federation, 454087
    • Chelyabinsk Regional Oncology Center - Phase 1
  • Engels, Russian Federation, 413115
    • Regional Oncology Center, Chemotherapy Department - Phase 2
  • Kazan, Russian Federation, 420111
    • Kazan Oncology Center
  • Moscow, Russian Federation, 115478
    • Blokhin Russian Oncology Research Center - Phase 1
  • Moscow, Russian Federation, 129128
    • Semashko Central Clinical Hospital #2 - Phase 1
  • Obninsk, Russian Federation, 249036
    • Medical Radiology Research Center of Russian Academy of Medical Sciences- Phase 1
  • Petrozavodsk, Russian Federation, 185007
    • Republic Oncology Center of the Ministry of Healthcare of Karelia Republic - Phase 2
  • Rostov-na-Dony, Russian Federation, 350086
    • Rostov Research Institute of Oncology- Phase 2
  • St. Petersburg, Russian Federation, 194291
    • St. Petersburg Academy of Postgraduate Education - Phase 2
  • St. Petersburg, Russian Federation, 195067
    • St. Petersburg Mechnikov State Medical Academy - Phase 2
  • St. Petersburg, Russian Federation, 198255
    • St. Petersburg City Oncology Center - Phase 1
  • Ulyanovsk, Russian Federation, 432063
    • Regional Clinical Oncology Center - Phase 2
  • Voronezh, Russian Federation, 394000
    • Voronezh Regional Clinical Oncology Center - Phase 2
  • Yaroslavl, Russian Federation, 150054
    • Yaroslavl Regional Oncology Center - Phase 1
  • Vsevolozhsk
    • Kuzmolovsky Village, Vsevolozhsk, Russian Federation, 188663
      • Leningrad Regional Oncology Center, Chemotherapy Department - Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the colon or rectum.
• Metastatic disease consistent with colorectal adenocarcinoma. Stage M1, and not amenable to curative surgery. Subjects with only locally persistent or only locally recurrent disease are not eligible.
• No prior systemic therapy for metastatic cancer. Prior adjuvant chemotherapy with a 5-FU-based treatment regimen not containing oxaliplatin or irinotecan is acceptable after a treatment-free interval of at least 6 months.
• ECOG performance score (PS) of 0 or 1.
• Life expectancy more than 3 months.
• Subject must have measurable disease, defined by the RECIST criteria.
• At least 28 days must have elapsed since prior surgery except venous access device placement.
• At least 28 days must have elapsed since prior radiotherapy.
• At least 28 days must have elapsed since a prior investigational agent.
• Absolute neutrophil count (ANC) equal to or greater than 1.5 x 10^9/L.
• Platelet count equal to or greater than 100 x 10^9/L.
• Hemoglobin equal or greater than 10g/dL (must be obtained at least 3 days after any transfusion).
• Serum AST and ALT levels less than or equal to 2.5 times upper limit of normal (ULN) or less than 5 times ULN if liver involvement is present.
• Serum bilirubin of less than or equal to 1.5 ULN.
• Serum creatinine of less than or equal to ULN.
• Women of childbearing potential must have a negative pregnancy test (serum or urine beta HCG).
• All subjects must agree to use appropriate birth control methods while on study and for 1 month after completion of study chemotherapy.

Exclusion Criteria:

• Concurrent use of EGFR inhibitors or anti-VEGF agents.
• No clinically significant obstructive symptoms or intestinal bleeding.
• Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g. Crohn's disease, ulcerative colitis, malabsorption syndrome, Grade 2+ diarrhea of any etiology at baseline).
• History of serious cardiac disease, defined as myocardial infarction within six months of enrollment, congestive heart failure classified by the New York Heart Association as class III or IV, uncontrolled cardiac arrhythmias, poorly controlled or unstable angina, or electrocardiographic evidence of acute ischemia.
• Clinical evidence of brain metastases or central nervous system disease.
• Symptomatic peripheral neuropathy (equivalent to Grade 2 or higher CTCAE toxicity criteria).
• Uncontrolled intercurrent illness (e.g. active infection).
• Pregnant or nursing.
• Serious medical or psychiatric illness that could potentially interfere with the completion of study treatment according to this protocol.
• Malignancy other than colorectal carcinoma within the past 5 years, except, curatively treated, superficial skin cancer or carcinoma in situ of the cervix or breast.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.	Drug: (FOLPI) Picoplatin with 5-FU and Leucovorin; Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.; Drug: FOLPI; Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Active Comparator: 2; FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.	Drug: FOLFOX; Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
dose-limiting toxicity	within the first four weeks of treatment
maximum tolerated dose	within the first two cycles of treatment

Secondary Outcome Measures

Outcome Measure	Time Frame
safety and efficacy	duration of the study

Collaborators and Investigators

• Sponsor: Poniard Pharmaceuticals

Publications and helpful links

General Publications

• Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res. 1997 Nov;3(11):2063-74.
• Beale P, Judson I, O'Donnell A, Trigo J, Rees C, Raynaud F, Turner A, Simmons L, Etterley L. A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). Br J Cancer. 2003 Apr 7;88(7):1128-34. doi: 10.1038/sj.bjc.6600854.
• Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 1998 Jan;13(1):1-18.
• Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer. 1998;77(3):366-73. doi: 10.1038/bjc.1998.59.
• Rogers P, Boxall FE, Allott CP, Stephens TC, Kelland LR. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur J Cancer. 2002 Aug;38(12):1653-60. doi: 10.1016/s0959-8049(02)00107-7.
• Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer. 2002 Nov;38(17):2309-15. doi: 10.1016/s0959-8049(02)00244-7.
• Douillard JY, Schiller J. ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies. Eur J Cancer. 2002 Dec;38 Suppl 8:S25-31. doi: 10.1016/s0959-8049(02)80020-x.
• Plasencia C, Abad A, Martinez-Balibrea E, Taron M. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. Invest New Drugs. 2004 Nov;22(4):399-409. doi: 10.1023/B:DRUG.0000036682.99818.71.
• Murakami H, Tamura T, Yamada Y, Yamamoto N, Ueda Y, Shimoyama T, Saijo N. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study. Eur J Cancer. 2002 Dec;38 Suppl 8:S1-5. doi: 10.1016/s0959-8049(02)80012-0.

Study record dates

Study Major Dates

• Study Start: April 1, 2006
• Primary Completion (Anticipated): December 1, 2009
• Study Completion (Anticipated): June 1, 2010

Study Registration Dates

• First Submitted: May 23, 2007
• First Submitted That Met QC Criteria: May 23, 2007
• First Posted (Estimate): May 25, 2007

Study Record Updates

• Last Update Posted (Estimate): January 21, 2009
• Last Update Submitted That Met QC Criteria: January 20, 2009
• Last Verified: January 1, 2009

More Information

Terms related to this study

• Keywords: colorectal cancer; chemotherapy; FOLFOX; picoplatin; FOLPI
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Physiological Effects of Drugs; Protective Agents; Micronutrients; Vitamins; Antidotes; Vitamin B Complex; Leucovorin
• Other Study ID Numbers: 0501